How exactly did you and your colleagues model the pharmacoeconomic effectiveness of alirocumab based on the actual results of the ODYSSEY Outcomes Trial?

How exactly did you and your colleagues model the pharmacoeconomic effectiveness of alirocumab based on the actual results of the ODYSSEY Outcomes Trial?

How exactly did you and your colleagues model the pharmacoeconomic effectiveness of alirocumab based on the actual results of the ODYSSEY Outcomes Trial?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Shaun Goodman, MD, MSc, FRCPC, FACC, FESC, FAHA

Associate Head, Division of Cardiology St. Michael’s Hospital